RBC Capital Downgrades Cardiome Pharma (CRME) to Sector Perform
More News related to CRME
- Cardiome (CRME) Announces That Collaboration and License Agreement with Merck & Co. (MRK)
- Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
- Cardiome Reports First Quarter Results
- Unusual 11 Mid-Day Movers 4/9: TXT, APWR, BAC, CRME Higher; FAZ, HPT, MTRX, ANF Lower
- Morning Movers 4/9: TXT, WFC, APWR, CRME, USB, EXM, BAC, GYMB, CSH Higher; MOV, ELMG, ANF Lower
RBC Capital downgrades Cardiome Pharma (Nasdaq: CRME) from Outperform to Sector Perform.
Cardiome Pharma Corp., through its subsidiaries, operates as a life sciences company that focuses on developing drugs to treat or prevent cardiovascular diseases.
Related Categories
DowngradesStocks Mentioned
+0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
